Search

is missing (Short communication)

Glioblastoma is the most common and aggressive primitive brain tumor in adults. Temozolomide (TMZ) administered daily with radiation therapy, followed by adjuvant TMZ has become the standard treatment. Although TMZ treatment has been considered to have a low toxicity profile, studies have noted the development of a severe myelosuppression, especially during the concomitant treatment; this toxicity may in some cases be prolonged and consequently treatment must be definitively discontinued. We analyzed two cases treated at our oncological center who developed severe and prolonged hematological toxicity during concomitant chemoradiotherapy treatment with TMZ. Hypothesizing that radiation therapy and daily TMZ could be the major causes of severe hematological toxicity during the concomitant phase, we decided to treat both patients with maintenance TMZ at the time of recovery of hematological values. Patients showed good tolerability without important myelosuppression. In conclusion, we suggest that glioblastoma patients with severe myelotoxicity during daily TMZ and radiation therapy be treated with maintenance TMZ at the time of blood value recovery.

Prevalence of symptomatic central nervous system (CNS) metastases among patients with breast cancer ranges from 5% to 16%, although autoptic studies have reported prevalence rates of up to 30%. Solid brain tumours are the most common presentation in the CNS (85-95%), and they tend to arise at the grey-white matter junction with a distribution that is proportional to the regional cerebral blood flow. Descriptions of solitary intra-ventricular metastasis are very rare; to date no cases from breast cancer have been reported in the literature. We present the unusual case of a breast cancer patient who developed a solitary choroid plexus metastasis in the left lateral ventricle.

INTRODUCTION Thrombolytic therapy for acute ischemic stroke is based on clinical assessment, blood tests, and computed tomography (CT) findings. The presence of early CT ischemic changes may help support therapeutic decision. Our aim is to call attention to a likely overlooked "stroke mimic," Gliomatosis Cerebri (GC). CASE SERIES Clinical and neuroimaging analysis of 3 patients with documented GC, whose acute clinical onset and CT data (lenticular and ribbon sign and a ipsilateral dot sign) were suggestive of ischemic stroke. CONCLUSION Noncerebrovascular conditions may present with both acute onset and false CT signs of early ischemic stroke. Although rare, GC needs to be considered among the possible "stroke mimics" to avoid inappropriate thrombolytic therapy.